Stock Research for TROV

TROV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TROV Stock Chart & Research Data

The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TROV Due diligence Resources & Stock Charts

The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TROV Detailed Price Forecast - CNN Money CNN View TROV Detailed Summary - Google Finance
Yahoo View TROV Detailed Summary - Yahoo! Finance Zacks View TROV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View TROV Trends & Analysis - Trade-Ideas Barrons View TROV Major Holders - Barrons
NASDAQ View TROV Call Transcripts - NASDAQ Seeking View TROV Breaking News & Analysis - Seeking Alpha
Spotlight View TROV Annual Report - CompanySpotlight.com OTC Report View TROV OTC Short Report - OTCShortReport.com
TradeKing View TROV Fundamentals - TradeKing Charts View TROV SEC Filings - Bar Chart
WSJ View Historical Prices for TROV - The WSJ Morningstar View Performance/Total Return for TROV - Morningstar
MarketWatch View the Analyst Estimates for TROV - MarketWatch CNBC View the Earnings History for TROV - CNBC
StockMarketWatch View the TROV Earnings - StockMarketWatch MacroAxis View TROV Buy or Sell Recommendations - MacroAxis
Bullish View the TROV Bullish Patterns - American Bulls Short Pains View TROV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View TROV Stock Mentions - StockTwits PennyStocks View TROV Stock Mentions - PennyStockTweets
Twitter View TROV Stock Mentions - Twitter Invest Hub View TROV Investment Forum News - Investor Hub
Yahoo View TROV Stock Mentions - Yahoo! Message Board Seeking Alpha View TROV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for TROV - SECform4.com Insider Cow View Insider Transactions for TROV - Insider Cow
CNBC View TROV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TROV - OTC Markets
Yahoo View Insider Transactions for TROV - Yahoo! Finance NASDAQ View Institutional Holdings for TROV - NASDAQ


Stock Charts

FinViz View TROV Stock Insight & Charts - FinViz.com StockCharts View TROV Investment Charts - StockCharts.com
BarChart View TROV Stock Overview & Charts - BarChart Trading View View TROV User Generated Charts - Trading View




Latest Financial News for TROV


Trovagene Presents Outlook for Second Half of 2018
Posted on Monday July 09, 2018

SAN DIEGO, July 9, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today provided an update on key value-creating milestones for the second half of 2018 and a review of its year-to-date achievements. "As a team, we achieved a number of key milestones in the first half of 2018 and we continue to execute on our business plan and to advancing our clinical development program in the second half of 2018. Looking ahead to the second half of 2018, the Company's Board of Directors is undertaking a search for a new CEO, who has the relevant therapeutic and drug development experience to lead Trovagene into its next stage.


Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
Posted on Wednesday June 27, 2018

Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b /2 trial in Acute Myeloid Leukemia (AML) SAN DIEGO , June 27, 2018 /PRNewswire/ -- Trovagene, ...


TrovaGene Enters Oversold Territor
Posted on Monday June 25, 2018

TrovaGene Enters Oversold Territor


Trovagene Announces Leadership Change
Posted on Friday June 22, 2018

William Welch has resigned as CEO and Director Dr. Thomas Adams, Chairman of the Board Appointed Interim CEO SAN DIEGO , June 22, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.